Harlan Waksal - Nov 9, 2021 Form 4 Insider Report for Kadmon Holdings, Inc. (KDMN)

Role
President, CEO, Director
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol
KDMN
Transactions as of
Nov 9, 2021
Transactions value $
$25,797,748
Form type
4
Date filed
11/9/2021, 04:42 PM
Previous filing
May 17, 2021
Next filing
Feb 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDMN Common Stock Disposed to Issuer -$1.69M -178K -100% $9.50 0 Nov 9, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDMN Stock Appreciation Right Disposed to Issuer $3.84M +655K $5.86 0 Nov 9, 2021 Common Stock, par value $0.001 655K $3.64 Direct F2, F3
transaction KDMN Performance Stock Option(right to buy) Disposed to Issuer $5.34M +983K $5.44 0 Nov 9, 2021 Common Stock, par value $0.001 983K $4.06 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer $7.22M +1.35M $5.35 0 Nov 9, 2021 Common Stock, par value $0.001 1.35M $4.15 Direct F2, F3
transaction KDMN Stock Option (right to buy) Disposed to Issuer $11.1M +2M $5.54 0 Nov 9, 2021 Common Stock, par value $0.001 2M $3.96 Direct F2, F3
transaction KDMN Equity Appreciation Rights Unit Disposed to Issuer $2.63K +750 $3.50 0 Nov 9, 2021 Common Stock, par value $0.001 750 $6.00 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Harlan Waksal is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
F2 In connection with the Merger, all unvested stock options ("Options"), stock appreciation rights ("SARs") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option, SAR and EAR award.
F3 Represents the payment per share of Common Stock received in exchange for the cancellation of each Option, SAR and EAR.